CEO ENDOMET (The Collider Programme)
Mobile World CapitalBarcelona, Catalonia, Spain
Posted February 10, 2026
Full Time
About the Company
ENDOMET, a deep-tech biotech project backed by the University of Granada, is developing MVP11, a first-in-class small molecule that restores mitochondrial energy by activating endogenous Coenzyme Q (CoQ) biosynthesis.
Job Description
CEO and Co-Founder Opportunity to build a science-driven biotech spin-off addressing rare mitochondrial diseases and female reproductive health. The project is developing a first-in-class small molecule that restores mitochondrial energy by activating endogenous Coenzyme Q (CoQ) biosynthesis.
Requirements
- Previous experience as founder or co-founder is highly valued.
- Strong understanding of rare diseases, regulatory pathways and go-to-market strategies.
- Experience with technology transfer and academic spin-offs.
- Comfortable operating at the intersection of science, regulation and business.
- Hands-on, resilient leader with long-term vision.
Benefits
- Relevant equity as CEO & Co-Founder upon company incorporation.
- €6,000 stipend during the validation phase (3 monthly instalments of €2,000).
- Access to The Collider venture-building programme.
- Access to The Collider and MWCapital ecosystem.
- Opportunity to access a participative loan of up to €50,000 to finance the first phases of the project.
- Coworking space in Barcelona (Tech Barcelona – Pier 01).